Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Apathy and impulsivity are debilitating conditions associated with many neuropsychiatric conditions, and expressed to variable degrees in healthy people. While some theories suggest that they lie at different ends of a continuum, others suggest their possible co-existence. Surprisingly little is known, however, about their empirical association in the general population. Here, gathering data from six large studies ([Formula: see text]), we investigated the relationship between measures of apathy and impulsivity in young adults. The questionnaires included commonly used self-assessment tools-Apathy Evaluation Scale, Barratt Impulsiveness Scale (BIS-11) and UPPS-P Scale-as well as a more recent addition, the Apathy Motivation Index (AMI). Remarkably, across datasets and assessment tools, global measures of apathy and impulsivity correlated positively. However, analysis of sub-scale scores revealed a more complex relationship. Although most dimensions correlated positively with one another, there were two important exceptions revealed using the AMI scale. Social apathy was mostly negatively correlated with impulsive behaviour, and emotional apathy was orthogonal to all other sub-domains. These results suggest that at a global level, apathy and impulsivity do not exist at distinct ends of a continuum. Instead, paradoxically, they most often co-exist in young adults. Processes underlying social and emotional apathy, however, appear to be different and dissociable from behavioural apathy and impulsivity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921138PMC
http://dx.doi.org/10.1038/s41598-021-84364-wDOI Listing

Publication Analysis

Top Keywords

apathy impulsivity
24
apathy
9
ends continuum
8
measures apathy
8
young adults
8
correlated positively
8
emotional apathy
8
impulsivity
6
relationship apathy
4
impulsivity large
4

Similar Publications

Noradrenergic therapies in neurodegenerative disease: from symptomatic to disease modifying therapy?

Brain Commun

August 2025

Department of Clinical Neurosciences and Cambridge University Hospitals NHS Foundation Trust, University of Cambridge, Cambridge CB2 0SZ, UK.

A feature shared by many different neurodegenerative diseases is early pathology and degeneration of the pontine locus coeruleus. The human locus coeruleus contains about 50 000 neurons and is the primary source of the neurotransmitter noradrenaline. We propose the hypothesis that noradrenergic drugs can have broad, transdiagnostic benefit in slowing or preventing the progression of neurodegenerative diseases.

View Article and Find Full Text PDF

Do we need drugs for psychiatric symptoms specifically for Parkinson's disease?

J Parkinsons Dis

August 2025

Department of Neurology, Norman Fixel Institute, University of Florida, Gainesville, FL, USA.

Although the need for better medications for the treatment of psychiatric symptoms in people with Parkinson's disease (PWP) is not disputed, the approach and targets for these medications needs further attention. Psychiatric symptoms occur at higher prevalence in PWP-many start in the prodromal phase of the disease-and have complex associations and interactions with the motor symptoms and their treatments, begging the question of whether they may be mechanistically connected. In this manuscript, we review the current evidence for pharmacologic treatments of psychiatric symptoms in PWP and explore the potential next steps needed to develop new medications for psychiatric symptoms in PD.

View Article and Find Full Text PDF

Neuropsychiatric disorders in Parkinson's disease.

Ther Adv Neurol Disord

July 2025

Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, Innsbruck 6020, Austria.

Neuropsychiatric symptoms, such as depression, anxiety, cognitive changes, apathy or hallucinations are common in patients with Parkinson's disease (PD). They can appear at any stage of the disease and some symptoms may even be a harbinger of PD. These neuropsychiatric complications often become more pronounced as PD progresses and may worsen particularly during 'off-periods'.

View Article and Find Full Text PDF

Introduction: Progressive supranuclear palsy (PSP) is a devastating neurodegenerative disease characterised by cognitive, behavioural and motor problems. Motor symptoms are highly disabling, while cognitive and behavioural changes have a major impact on carer burden, quality of life and prognosis. Apathy and impulsivity are very common, often coexistent in PSP, and negatively predict survival.

View Article and Find Full Text PDF

Background: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for people with Parkinson's disease (PwP). However, some patients treated with DBS may still experience quality of life limiting impairments after surgery, e.g.

View Article and Find Full Text PDF